Literature DB >> 18828945

Do individuals consider expected income when valuing health states?

Thomas Davidson1, Lars-Ake Levin.   

Abstract

OBJECTIVES: The purpose of this study was to empirically explore whether individuals take their expected income into consideration when directly valuing predefined health states. This was intended to help determine how to handle productivity costs due to morbidity in a cost-effectiveness analysis.
METHODS: Two hundred students each valued four hypothetical health states by using time trade-off (TTO) and a visual analogue scale (VAS). The students were randomly assigned to two groups. One group was simply asked, without mentioning income, to value the different health states (the non-income group). The other group was explicitly asked to consider their expected income in relation to the health states in their valuations (the income group).
RESULTS: For health states that are usually assumed to have a large effect on income, the valuations made by the income group seemed to be lower than the valuations made by the non-income group. Among the students in the non-income group, 96 percent stated that they had not thought about their expected income when they valued the health states. In the income group, 40 percent believed that their expected income had affected their valuations of the health states.
CONCLUSION: The results show that, as long as income is not mentioned, most individuals do not seem to consider their expected income when they value health states. This indicates that productivity costs due to morbidity are not captured within individuals' health state valuations. These findings, therefore, suggest that productivity costs due to morbidity should be included as a cost in cost-effectiveness analyses.

Mesh:

Year:  2008        PMID: 18828945     DOI: 10.1017/S0266462308080641

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  6 in total

1.  Does the EQ-5D reflect lost earnings?

Authors:  Carl Tilling; Marieke Krol; Aki Tsuchiya; John Brazier; Job van Exel; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2012-01       Impact factor: 4.981

Review 2.  Productivity costs in economic evaluations: past, present, future.

Authors:  Marieke Krol; Werner Brouwer; Frans Rutten
Journal:  Pharmacoeconomics       Date:  2013-07       Impact factor: 4.981

3.  How to estimate productivity costs in economic evaluations.

Authors:  Marieke Krol; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2014-04       Impact factor: 4.981

Review 4.  Do productivity costs matter?: the impact of including productivity costs on the incremental costs of interventions targeted at depressive disorders.

Authors:  Marieke Krol; Jocé Papenburg; Marc Koopmanschap; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2011-07       Impact factor: 4.981

5.  Do the Washington Panel recommendations hold for Europe: investigating the relation between quality of life versus work-status, absenteeism and presenteeism.

Authors:  Saskia Knies; Annelies Boonen; Johan L Severens
Journal:  Cost Eff Resour Alloc       Date:  2014-11-24

6.  A cross-sectional survey of work and income loss consideration among patients with herpes zoster when completing a quality of life questionnaire.

Authors:  Kelly D Johnson; Susan K Brenneman; Chrisann Newransky; Seth Sheffler-Collins; Laura K Becker; Angela Belland; Camilo J Acosta
Journal:  BMC Health Serv Res       Date:  2018-08-25       Impact factor: 2.655

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.